X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/innovent-announces-overall-survival-results-of-phase-2-study-of-pemazyre-pemigatinib-in-chinese-patients-with-advanced-cholangiocarcinoma-presented-at-aacr-annual-meeting-2023-301798880.html
https://www.prnewswire.com/news-releases/new-treatment-for-rare-cancer-cholangiocarcinoma-approved-in-australia-301625157.html
https://www.pharmaceutical-technology.com/news/fda-approves-incyte-pemazyre/
https://www.prnewswire.com/news-releases/innovent-announces-the-approval-of-pemazyre-pemigatinib-by-the-nmpa-for-the-treatment-of-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion-or-rearrangement-as-confirmed-by-a-validated-diagnostic--301518629.html
https://www.globenewswire.com/news-release/2022/01/31/2376027/0/en/Non-Muscle-Invasive-Bladder-Cancer-Pipeline-Insights-Clinical-Trials-Report-2022-by-DelveInsight.html
https://www.prnewswire.com/news-releases/innovent-announces-the-approval-of-pemazyre-pemigatinib-in-hong-kong-market-for-the-treatment-of-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion-or-rearrangement-that-have-progressed-after-at-l-301466319.html
https://www.biospace.com/article/releases/incyte-announces-health-canada-conditional-approval-of-pemazyre-and-174-pemigatinib-as-first-targeted-treatment-for-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma/?s=71
https://www.prnewswire.com/news-releases/innovent-announces-nmpa-acceptance-of-new-drug-application-for-the-fgfr123-inhibitor-pemigatinib-for-the-treatment-of-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2--301328287.html
https://www.businesswire.com/news/home/20210129005533/en/Incyte-Announces-Positive-CHMP-Opinion-for-Pemigatinib-for-the-Treatment-of-Adults-With-Previously-Treated-Unresectable-Locally-Advanced-or-Metastatic-Cholangiocarcinoma-With-a-Fibroblast-Growth-Factor-Receptor-2-FGFR2-Fusion-or-Rearrangement
https://www.newswire.ca/news-releases/incyte-announces-health-canada-acceptance-of-the-new-drug-submission-for-pemigatinib-as-a-treatment-for-patients-with-cholangiocarcinoma-837020917.html
https://www.pmlive.com/pharma_news/fda_approves_incytes_pemazyre_as_first_targeted_drug_for_bile_duct_cancer_1338622
https://en.prnasia.com/releases/global/innovent-biologics-announces-fda-approval-of-pemazyre-pemigatinib-as-first-targeted-treatment-for-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-277788.shtml
https://www.prnewswire.com/news-releases/innovent-biologics-announces-fda-acceptance-of-nda-for-pemigatinib-in-patients-with-previously-treated-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusions-or-rearrangements-300967035.html
https://www.prnewswire.com/news-releases/innovent-biologics-announces-fda-acceptance-of-nda-for-pemigatinib-in-patients-with-previously-treated-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusions-or-rearrangements-300967035.html
https://www.biospace.com/article/releases/innovent-biologics-announces-positive-updated-result-from-the-incyte-sponsored-phase-ii-trial-of-pemigatinib-in-patients-with-previously-treated-advanced-cholangiocarcinoma/?s=95
https://www.biospace.com/article/releases/innovent-biologics-announces-positive-updated-result-from-the-incyte-sponsored-phase-ii-trial-of-pemigatinib-in-patients-with-previously-treated-advanced-cholangiocarcinoma/?s=95
https://www.prnewswire.com/news-releases/innovent-and-incyte-announce-strategic-collaboration-and-licensing-agreement-for-three-clinical-stage-product-candidates-in-china-300767163.html
https://www.businesswire.com/news/home/20181009005352/en/Incyte-Announces-Data-Pemigatinib-Selective-FGFR-Inhibitor
Market Place
Share 
